Open Access. Powered by Scholars. Published by Universities.®

Pharmacology Commons

Open Access. Powered by Scholars. Published by Universities.®

University of Louisville

2019

Discipline
Keyword
Publication
Publication Type

Articles 31 - 43 of 43

Full-Text Articles in Pharmacology

Human Ecology, Spring/Summer 2016, Issue 34 Sep 2019

Human Ecology, Spring/Summer 2016, Issue 34

Sustain Magazine

No abstract provided.


Citizen Science, Fall/Winter 2016, Issue 33 Sep 2019

Citizen Science, Fall/Winter 2016, Issue 33

Sustain Magazine

No abstract provided.


Urban Streams, Spring/Summer 2015, Issue 32 Sep 2019

Urban Streams, Spring/Summer 2015, Issue 32

Sustain Magazine

No abstract provided.


Unconventional Energy, Fall/Winter 2015, Issue 31 Sep 2019

Unconventional Energy, Fall/Winter 2015, Issue 31

Sustain Magazine

No abstract provided.


Carbon Neutral, Spring/Summer 2018, Issue 38 Sep 2019

Carbon Neutral, Spring/Summer 2018, Issue 38

Sustain Magazine

No abstract provided.


Political Will, Fall/Winter 2018, Issue 37 Sep 2019

Political Will, Fall/Winter 2018, Issue 37

Sustain Magazine

No abstract provided.


Our Envirome, Spring/Summer 2019, Issue 40 Aug 2019

Our Envirome, Spring/Summer 2019, Issue 40

Sustain Magazine

No abstract provided.


Plastic Pollution, Fall/Winter 2019, Issue 39.3 Aug 2019

Plastic Pollution, Fall/Winter 2019, Issue 39.3

Sustain Magazine

No abstract provided.


Plastic Pollution, Fall/Winter 2019, Issue 39.2 Aug 2019

Plastic Pollution, Fall/Winter 2019, Issue 39.2

Sustain Magazine

No abstract provided.


Plastic Pollution, Fall/Winter 2019, Issue 39 Aug 2019

Plastic Pollution, Fall/Winter 2019, Issue 39

Sustain Magazine

No abstract provided.


Paraoxonase 2 Is Critical For Non-Small Cell Lung Carcinoma Proliferation., Aaron Whitt May 2019

Paraoxonase 2 Is Critical For Non-Small Cell Lung Carcinoma Proliferation., Aaron Whitt

Electronic Theses and Dissertations

Non-small cell lung carcinoma (NSCLC) comprises 85% of lung cancer diagnoses and is plagued by drug resistance. Thus, elucidating the underlying mechanisms of NSCLC is paramount to expand future treatment options. Paraoxonase 2 (PON2), an intracellular enzyme with arylesterase and lactonase functions, has well-established anti-atherosclerotic activity. Recent studies show PON2 is overexpressed in a variety of tumors and confers drug resistance, although these interactions have not been thoroughly examined in NSCLC. Thus, we sought to investigate the role of PON2 in cellular proliferation using PON2-knockout mice, primary mouse cells, and NSCLC cell lines. Using these approaches, we demonstrate that PON2 …


Development Of Bar-Peptide Nanoparticles And Electrospun Fibers For The Prevention And Treatment Of Oral Biofilms., Mohamed Yehia Mahmoud May 2019

Development Of Bar-Peptide Nanoparticles And Electrospun Fibers For The Prevention And Treatment Of Oral Biofilms., Mohamed Yehia Mahmoud

Electronic Theses and Dissertations

Background: Periodontal diseases are globally prevalent inflammatory disorders that affect ~47% of U.S adults. Porphyromonas gingivalis (Pg) has been identified as a “keystone” pathogen that disrupts host-microbe homeostasis and contributes to the initiation and progression of periodontitis. Pg associates with oral streptococci in supragingival plaque and this interaction represents a potential target for therapeutic intervention. Previously our group developed a peptide (designated BAR), that potently inhibits Pg/Streptococcus gordonii (Sg) adherence in vitro and Pg virulence in a murine model of periodontitis. While efficacious, BAR (SspB Adherence Region) provided transient inhibition and required higher concentrations of BAR to disrupt established …


Development Of A Lectin-Fc Fusion Protein With Antiviral And Anti-Cancer Activity., Matthew William Dent May 2019

Development Of A Lectin-Fc Fusion Protein With Antiviral And Anti-Cancer Activity., Matthew William Dent

Electronic Theses and Dissertations

This thesis describes the development of a novel lectin-Fc fusion protein and its antiviral and anti-cancer activity. The molecule, Avaren-Fc (AvFc), is a fusion of a variant of the actinomycete lectin actinohivin (Avaren) and the Fc region of human IgG1, and is selective for the terminal α1,2-mannose residues found at the ends of high-mannose-type glycans that can be found on the surface of certain heavily glycosylated viruses and cancer cells. Here, AvFc was found to be able to neutralize simian immunodeficiency virus as well as Hepatitis C virus with nanomolar IC50 values. Furthermore, AvFc recognizes a number of cell …